<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly!

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Ovarian Cancer PDX Models

The Crown Bioscience ovarian cancer patient-derived xenograft (PDX) collection consists of several models including a treatment resistant model. PDX models present a true representation of the human heterogeneity of gynecologic malignancies and provide the most accurate approach to predicting an agents efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
OV0243 Ovarian Cancer Papillary adenocarcinoma Pathology QC: Papillary adenocarcinoma (P4, P7). CLICK TO VIEW
OV0250 Ovarian Cancer Endometrioid adenocarcinoma Mixed adenocarcinoma of ovary. Endometrioid adenocarcinoma, grade III, invaded the uterine wall. CLICK TO VIEW
OV0273 Ovarian Cancer NA Embryonal carcinoma of right ovary. No malignant cells adjacent to right oviduct. IHC results: CD56(+/-),Syn(+/-),CK(+/-),CD117(+/-),AR(-), PLAP(-), CA1259(-). CLICK TO VIEW
OV0276 Ovarian Cancer ADC Mucinous adenocarcinoma of ovary (could not exclude Krukenberg's tumor). No malignant cells adjacent to oviduct and perimetrium. Regional LN: LN of abdominal aorta (2/2). CLICK TO VIEW
OV0589 Ovarian Cancer NA NA for clinical diagnosis info. Pathology QC: Papillary adenocarcinoma (Pa, P1) CLICK TO VIEW
OV1200 Ovarian Cancer ADC Adenocarcinoma of both ovary and oviduct, poorly to moderately differentiated. CLICK TO VIEW
OV1272 Ovarian Cancer cystadenoma Mucinous cystadenoma of bilateral ovary. The tumor of bilateral adnexa uteri forms irregular glandular structures and has an infiltrative growth pattern. IHC results: PR(-), ER(-), CK7(+), CK20(-), Villin(+). CLICK TO VIEW
OV1286 Ovarian Cancer ADC Adenocarcinoma of right ovary. CLICK TO VIEW
OV1327 Ovarian Cancer Serous papillary cystadenocarcinoma Papillary serous cystadenocarcinoma of right ovary. The tumor forms irregualar papillary glandular structures and has an infiltrative growth pattern. Columnar epithelial cells may be seen. The neoplastic cells invasive pelvic cavity and greater omentum. CLICK TO VIEW
OV1365 Ovarian Cancer ADC Mixed epithelial malignant tumor of left ovary, include serous adenocarcinoma, clear cell carcinoma and hepatoid adenocarcinoma. Tumor forms nest and papillary structures and has an infiltrative growth pattern. Regional LN: left obturator LN (1/6), left inguinal LN (0/3), left internal and external iliac (0/4), left common iliac LN (0/7), right common iliac LN (0/2), right internal and external iliac LN (0/5), right inguinal LN (0/4), right obturator LN (0/4). CLICK TO VIEW
OV1385 Ovarian Cancer Cystadenoma 1. Mucous cystadenocarcinoma of bilateral ovary. The tumor forms adenoid tubular and nest structures and has an infiltrative growth pattern. Malignant cells are viewed within bilateral fimbriae oviduct.Regional LN: LN of greater omentum (0/3). 2. Chronic appendicitis CLICK TO VIEW
OV13950 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV1396 Ovarian Cancer NA Poorly differentiated serous papillary carcinoma of bilateral oviduct and involving bilateral ovary. The tumor forms irregular papillary, solid forms and has an infiltrative growth pattern. Regional LN: LN of right abdominal aorta (3/4), left obturator LN (1/3), right obturator LN (2/3), left groin LN (2/2), left interna and external iliac LN (1/1), right common iliac (1/3), right gorin (0/3), left common iliac LN (0/4). CLICK TO VIEW
OV14654 Ovarian Cancer N/A N/A CLICK TO VIEW
OV14972 Ovarian Cancer NA Ovarian Carcinoma. Pathol comment: C/W REFERRING DIAGNOSIS. MICROSCOPIC FOCUS OF MALIGNANT TUMOR PRESENT IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. CLICK TO VIEW
OV15013 Ovarian Cancer NA Metastatic serous papillary carconoma, PD. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 80% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. CLICK TO VIEW
OV15398 Ovarian Cancer NA Ovarian Carcinoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. CLICK TO VIEW
OV15612 Ovarian Cancer NA Ovarian Carcinoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 100% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. FOCAL TUMOR NECROSIS. APPROXIMATELY 70% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. CLICK TO VIEW
OV15631 Ovarian Cancer NA Ovarian Carcinoma. Pathol comment: MALIGNANT TUMOR CELLS PRESENT IN CELL BLOCK. APPROXIMATELY 90% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. C/W DIAGNOSIS. CLICK TO VIEW
OV1579 Ovarian Cancer NA Left ovary: moderately-poorly differentiated adenocarcinoma. CLICK TO VIEW
OV15841 Ovarian Cancer NA H/O ovarian carcinoma, RECURRENT UNDIFFERENTIATED CARCINOMA. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 80% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. APPROXIMATELY 80% MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREPARATION. CLICK TO VIEW
OV1658 Ovarian Cancer NA Small cell undifferentiated carcinoma CLICK TO VIEW
OV2015 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV2017 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV2018 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV2026 Ovarian Cancer NA Carcinosarcoma, NOS CLICK TO VIEW
OV2027 Ovarian Cancer Serous papillary cystadenocarcinoma Papillary serous cystadenocarcinoma CLICK TO VIEW
OV2029 Ovarian Cancer NA Mixed cell adenocarcinoma CLICK TO VIEW
OV2034 Ovarian Cancer Serous cystadenocarcinoma Serous cystadenocarcinoma, NOS CLICK TO VIEW
OV2423 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV2546 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV3355 Ovarian Cancer Serous adenocarcinoma Bilateral ovaries: poorly differentiated serous adenocarcinoma. One of one lymph node involved by malignant carcinoma (1/1). CLICK TO VIEW
OV3395 Ovarian Cancer Serous papillary cystadenocarcinoma Right ovary: serous papillary cystadenocarcinoma CLICK TO VIEW
OV3414 Ovarian Cancer Serous adenocarcinoma Pelvic cavity and right ovary: serous adenocarcinoma, moderately differentiated CLICK TO VIEW
OV3425 Ovarian Cancer Serous papillary cystadenocarcinoma Bilateral ovaries: serous papillary adenocarcinoma, moderately differentiated. The tumor infiltrated omentum majus and vermix. Six of nineteen lymph nodes involved by malignant carcinoma (6/19). CLICK TO VIEW
OV3596 Ovarian Cancer ADC Left ovay: poorly differentiated adenocarcinoma, tend to mucinous adenocarcinoma with endometrioid adenocarcinoma CLICK TO VIEW
OV3692 Ovarian Cancer Adenocarcinoma NA CLICK TO VIEW
OV3708 Ovarian Cancer Mucinous adenocarcinoma Right ovary and fallopian tube: moderately to poorly differentiated mucinous adenocarcinoma. CLICK TO VIEW
OV3756 Ovarian Cancer Serous adenocarcinoma Pelvic cavity: moderately differentiated serous adenocarcinoma, consider infiltrating or implanted ovarian serous adenocarcinoma on the basis of medical history CLICK TO VIEW
OV5287 Ovarian Cancer Ovarian (high grade) ADENOCARCINOMA, MUCINOUS. CLICK TO VIEW
OV5294 Ovarian Cancer mucinous adenocarcinoma ovarian carcinoma mucinous adenocarcinoma. Pathol comment: c/w diagnosis. approximately 60% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
OV5296 Ovarian Cancer cystadenocarcinoma ovarian carcinoma mucinous cystadenocarcinoma. Pathol comment: c/w referring diagnosis. malignant cell present in cell block and cytospin prep. CLICK TO VIEW
OV5297 Ovarian Cancer clear cell carcinoma ovarian carcinoma clear cell adenocarcinoma, high grade. Pathol comment: c/w diagnosis. approximately 70% of the tissue involved by malignant tumor in sections examined. 20% necrosis. approximately 80% malignant tumor cells present in cytospin preparation. CLICK TO VIEW
OV5298 Ovarian Cancer ADC ovarian carcinoma metastastic mucin producing adenocarcinoma. Pathol comment: approximately 80% of the tissue involved by malignant tumor in sections examined. consistent with mucinous adenocarcinoma. approximately 70% malignant tumor cells present in cytospin preparation. CLICK TO VIEW
OV5304 Ovarian Cancer serous carcinoma (high grade) carcinomatosis, ovarian malignant tumor high grade, grade 3, serous carcinoma extensively involving the omentum, splenic capsule, and preipancreatic tissue CLICK TO VIEW
OV5308 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV5390 Ovarian Cancer NA Ovarian Cancer CLICK TO VIEW
OV5391 Ovarian Cancer N/A Ovarian cancer patient-derived xenograft (PDX) model OV5391. Cancer Type: Ovarian Cancer, Metastatic Serous Carcinoma. Cancer Sub-type: Serous Carcinoma. This model is from the same patient as OV5392. CLICK TO VIEW
OV5392 Ovarian Cancer Serous Carcinoma Ovarian cancer patient-derived xenograft (PDX) model OV5392. Cancer Type: Ovarian Cancer, Metastatic Serous Carcinoma. Cancer Sub-type: Serous Carcinoma. This model is from the same patient as OV5391. CLICK TO VIEW
OV5397 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV5398 Ovarian Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
OV6308 Ovarian Cancer Serous Adenocarcinoma Bilateral ovaries: serous adenocarcinoma, high-grade CLICK TO VIEW
OV9399 Ovarian Cancer NA NA CLICK TO VIEW
OV9408 Ovarian Cancer NA metstatic adenocarcinoma CLICK TO VIEW
OV9413 Ovarian Cancer NA NA CLICK TO VIEW
OV9419 Ovarian Cancer Serous carcinoma NA CLICK TO VIEW
OV9421 Ovarian Cancer Adenocarcinoma NA CLICK TO VIEW
OV9422 Ovarian Cancer Mixed epithelial carcinoma NA CLICK TO VIEW
OV9423 Ovarian Cancer N/A N/A CLICK TO VIEW
OV9427 Ovarian Cancer ADC N/A CLICK TO VIEW
OV9428 Ovarian Cancer NA NA CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login